BioSpace News Archive

The injectable non-thrombin foam, LifeFoam™, created by Medcura Inc., a commercial-stage life science and medical device company, increased the amount of time swine could survive severe internal bleeding in a recent study.

Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the annual VIVA and The VEINS conferences at Wynn Las Vegas.

Longboard Pharmaceuticals, Inc. announced that members of its senior leadership team will participate in the Citi Annual BioPharma Conference, which is taking place September 7-8, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022, in New York City.

Catalyst Biosciences, Inc. announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022.

Liminal BioSciences Inc. announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market that the Company’s application to transfer its common shares from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810, had been approved.

Senseonics Holdings, Inc. announced its Chief Financial Officer, Nick Tressler, is transitioning from his position, effective September 1, 2022.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 13, 2022 at 11:10 a.m. ET.

ImmunoGen, Inc. announced that on August 31, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 883,720 shares of its common stock to twenty-four new employees under the ImmunoGen, Inc.

Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 7,600 shares of TCR2’s common stock to 2 new non-executive employees.